Mylan Receives FDA Approval and 180 Day Exclusivity for NitrofurantoinPITTSBURGH--(BUSINESS WIRE)--March 24, 2004--Mylan Laboratories Inc. (NYSE: MYL) is pleased to announce that the U.S. Food and Drug Administration has granted final approval for Mylan Pharmaceuticals' Abbreviated New Drug Application for nitrofurantoin monohydrate/macrocrystals capsules, 100 mg. Nitrofurantoin is the generic version of Procter & Gamble's Macrobid^®.

Mylan was the first company to file a paragraph IV certification for nitrofurantoin, and as such is entitled to 180 days of marketing exclusivity.

Mylan intends to ship the product immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the immediate launch, and marketing exclusivity, of nitrofurantoin. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the possible negative effects of any interruption of manufacture of the capsules at the Company's facility; uncertainties regarding market acceptance and demand for nitrofurantoin; dependence on third-party suppliers and distributors for raw materials; the potential costs and product introduction delays that may result from use of legal, regulatory and legislative strategies by the Company's competitors; and the other risks detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    CONTACT: Mylan Laboratories Inc.
             Kris King, 724-514-1800

    SOURCE: Mylan Laboratories Inc.